J2327 HCPCS code: Injection, risankizumab-rzaa, intravenous, 1 mg
J2327 is the HCPCS Level II code for injection, risankizumab-rzaa, intravenous, 1 mg. In 2024 Medicare paid an average of $11.22 per service for J2327 across 2,874,047 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 1200 per day on DME suppliers. Medicare volume rose 93% from 2023 to 2024 (1,490,899 to 2,874,047 services). In 2024, about 1,804 clinicians billed Medicare for J2327 for 1,965 beneficiaries; Florida, Texas, California accounted for 27% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-01-01 |
| Last action effective | 2023-01-01 |
Who bills J2327 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,804 |
| Medicare beneficiaries | 1,965 |
| States with claims | 37 |
| Share of services in top 3 states (Florida, Texas, California) | 27% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2327, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 1,490,899 | 1,143 | $14.51 | $11.56 |
| 2024 | 2,874,047 | 1,965 | $14.09 | $11.22 |
States with the most J2327 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 331,711 | $11.08 |
| Texas | 263,620 | $10.75 |
| California | 161,708 | $11.49 |
| New York | 136,517 | $11.29 |
| Illinois | 135,304 | $11.45 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 1200 | Prescribing Information |
| outpatient hospital claims | 1200 | Prescribing Information |
| practitioner claims | 1200 | Prescribing Information |
What changed for J2327
- 2023-01-01: J2327 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2327?
J2327 is the HCPCS Level II code for injection, risankizumab-rzaa, intravenous, 1 mg. Short descriptor: "Inj risankizumab-rzaa 1 mg".
How much does Medicare pay for J2327?
In 2024, the average Medicare payment was $11.22 per service (average allowed $14.09).
Does Medicare cover J2327?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2327 can be billed per day?
1200 on DME suppliers; 1200 on outpatient hospital claims; 1200 on practitioner claims (NCCI medically unlikely edits).
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2329 — Injection, ublituximab-xiiy, 1mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2327
- Watch J2327 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2327
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.